FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Cytokinetics (CYTK) announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

Agents Inhibiting CYP3A Metabolism: Caution is recommended when administering IMKELDI with strong CYP3A4 inhibitors. Grapefruit juice should be avoided. Imatinib is a CYP3A substrate. Concomitant ...

and fluoxetine (inhibitor of 2C19 and 2D6). The data show that aficamten was eliminated by multiple CYP pathways, primarily by CYP2C9 (fraction metabolized [fm]=50%), with contributions from CYP3A ...

Because posaconazole is a CYP3A4 inhibitor, oncology drugs that are CYP3A substrates must be paused during posazonazole treatment, with a washout period before restarting. The half-life of ...

Dosage modifications are recommended for patients with moderate to severe hepatic impairment and for those taking moderate CYP3A inhibitors (Figure 3). The concomitant use of Journavx and strong ...

strong inducers of CYP3A enzymes, strong inhibitors of CYP2C9 and/or strong or moderate dual inhibitors of CYP2C9/CYP3A); and 2. patients, who are poor CYP2C9 metabolizers receiving concomitant ...

which is known to inhibit CYP3A enzymes and alter tacrolimus metabolism. Additionally, no patients were prescribed erythromycin, fluoxetine, paroxetine, ketoconazole, itraconazole, azamulin, or ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...

If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that ...